Bionik Laboratories Advances InMotion AnkleBot into Commercial Development
/
Date20 Dec 2016
– InMotion AnkleBot developed at MIT by preeminent leaders in robotics technology development – – AnkleBot is designed to address major complications for stroke patients... Read More →
Nabriva Achieves 60% Randomization Target in LEAP 1 Phase 3 Trial in Community Acquired Bacterial Pneumonia
/
Date20 Dec 2016
-Blinded interim analysis to confirm sample size expected in February 2017 VIENNA, Austria and KING OF PRUSSIA, Pa., Dec. 20, 2016 (GLOBE NEWSWIRE) — Nabriva... Read More →
Pluristem and Sosei CVC to Establish a New Corporation for the Commercialization of PLX-PAD in Japan
/
Date20 Dec 2016
Pluristem and Sosei CVC will establish a new corporation which will pursue the clinical development and commercialization of PLX-PAD in Japan The first indication to... Read More →
Global mHealth Market will reach USD 102.43 Billion by 2022: Zion Market Research
/
Date20 Dec 2016
Sarasota, FL, Dec. 20, 2016 (GLOBE NEWSWIRE) — Zion Market Research has published a new report titled “mHealth Market by Devices, by Stakeholder, by Service,... Read More →
Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364
/
Date20 Dec 2016
Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364 Ogeda, a clinical-stage drug discovery company that invents and develops small molecule drug... Read More →
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.
/
Date20 Dec 2016
Media release (PDF).pdf Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc. to add first-in-class disease modifying... Read More →
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Endometriosis
/
Date19 Dec 2016
THE WOODLANDS, Texas, Dec. 19, 2016 (GLOBE NEWSWIRE) — Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has requested a meeting to discuss Phase 3 requirements... Read More →
Conatus Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan
/
Date19 Dec 2016
– Conference Call and Webcast Presentation at 5:30 p.m. ET Today – – Continuing Initial Focus on NASH Cirrhosis with Parallel Development in NASH Fibrosis... Read More →
OpGen Supports Passage of Landmark 21st Century Cures Act to Expedite Development of Solutions for Bacterial Infections
/
Date19 Dec 2016
GAITHERSBURG, Md., Dec. 19, 2016 (GLOBE NEWSWIRE) — OpGen, Inc. (NASDAQ:OPGN) issued the statement below following the passage of the 21st Century Cures legislation in... Read More →
Elbit Imaging Ltd. Announces That INSIGHTEC's Exablate Neuro System Has Been Approved by MHLW (Japan) for the Treatment of Essential Tremor and That INSIGHTEC's Exablate System Has Been Approved by EU (CE) for the Treatment of Prostate Cancer
/
Date19 Dec 2016
TEL AVIV, Israel, Dec. 19, 2016 (GLOBE NEWSWIRE) — Elbit Imaging Ltd. (TASE:EMITF) (NASDAQ:EMITF) (“Elbit” or the “Company“) announced today that it was informed by INSIGHTEC... Read More →